Press Release

June 19 2024

PINOVA Capital invests in NEUROMEDEX

Specialist in neurosurgical products, NEUROMEDEX, arranges succession and continues successful growth path.

Together with Managing Director Markus Drewes, funds advised by PINOVA Capital GmbH (“PINOVA”) have agreed to acquire shares in the NEUROMEDEX group (“NEUROMEDEX”) from company founder Marco Geyer. The parties have agreed to keep the terms of this transaction confidential.

NEUROMEDEX is a leading provider of disposable products for neurosurgery and intensive care, based in Hamburg, Germany. NEUROMEDEX products allow neurosurgeons to monitor and regulate intracranial pressure in their patients' brains with minimal infection risk.

The company and products set themselves apart by innovative solutions of the highest quality and usability, supporting doctors worldwide in saving lives day by day. In line with that, NEUROMEDEX products are highly valued by a broad and loyal customer base of hospitals, purchasing groups, and distributors domestically and internationally.

Marco Geyer, company founder and long-time Managing Director of NEUROMEDEX, emphasizes: "I am proud to have developed NEUROMEDEX into an innovative niche market leader with my employees and am now pleased to hand over the company to my long-time colleague and co-managing director Markus Drewes, as well as an experienced, value-oriented, partner like PINOVA that is well acquainted with the German Mittelstand. I would also like to thank our transaction advisor Livingstone Partners, particularly Jochen Hense, Matti Schroeder, and Lukas Windfuhr, for their trustworthy collaboration and advice, which enabled us to find the ideal partner."

Jochen Hense of Livingstone Partners adds: "It is always a special feeling to support successful companies and entrepreneurs in finding the right partner for the future. We are pleased to have accompanied Mr. Geyer on this journey and congratulate him and PINOVA on the successful transaction."

Markus Drewes, who has also invested in NEUROMEDEX as part of the transaction, comments: "We are very pleased to have found a partner in PINOVA who brings extensive experience in the strategic development and internationalization of mid-sized companies. Together with our team of long-term employees, who we are very proud of, and PINOVA we will push the go-to-market of new innovative products and the expansion of our international sales network.”

David Gilli, Director at PINOVA Capital, adds: "We are pleased to support Mr. Geyer in his company succession and are excited to lead this unique company into the next growth phase. As managing director and long-term senior employee, Markus Drewes, who has invested in the company alongside us, will significantly shape the course of success for the coming years. Together, we will further tap the growth potential of NEUROMEDEX within Europe and the rest of the world. We are very much looking forward to working together with him and the team."

PINOVA was advised on the transaction by CMS (Legal), Singular (Market), AC Christes (Finance and Tax as well as Structuring), Regular Services (IP and Product), and Goodwin (Financing Documentation).

Marco Geyer was advised by Livingstone Partners (Sell-Side M&A) and BSP (Legal and Tax).

About NEUROMEDEX

NEUROMEDEX is a globally active company specializing in the development and production of disposable neurosurgical products, based in Hamburg, Germany. The current team of 70 employees is driven by the aspiration to develop user-optimized product solutions for highest patient safety. For more information, visit: neuromedex.com

About PINOVA Capital

PINOVA Capital is an independent private equity company that invests its managed funds in high-growth technology companies in the German-speaking region. PINOVA focuses on mid-sized companies with revenues between €10 million and €75 million in the Industrial Technology sector, characterized by significant growth potential, sustainable competitive advantages, and a strong market position in their niche. For more information, visit: pinovacapital.com

Back to overview